Major Developments: Everest MED (01952) announced that the technology related to its original product Nefecon® is protected in China by patent ZL200980127272.5, which is currently in a valid state. UNI-BIO GROUP (00690) has entered into a strategic partnership with the National Engineering Research Center of Wenzhou Medical University and the People's Government of Ouhai District, Wenzhou City. HUTCHMED (00013) announced that the New Drug Application for savolitinib for the treatment of gastric cancer patients with MET amplification has been accepted in China and granted priority review status. FOSUN PHARMA (02196) disclosed that its controlling subsidiary has initiated a Phase I clinical trial in China for the theranostic radiopharmaceutical project SRT-007. Postal Savings Bank of China (01658) announced that its absorption and merger of Youhui Wanjia Bank has been approved by the National Financial Regulatory Administration. MicroPort CardioFlow Medtech (02160) officially released the one-year follow-up results from the Early Feasibility Study of AltaValve™. Operating Performance: New Huo Technology Holdings (01611) reported its annual results, revealing a loss attributable to company owners of HK$9.212 million, a shift from profit to loss year-on-year. Singamas Development (00640) announced its annual results, posting a net profit of approximately HK$122 million, a 21.7% increase year-on-year. Zijin Mining Group (02899) forecasts its 2025 annual net profit attributable to owners to be approximately RMB 51 billion to RMB 52 billion, representing an increase of about 59% to 62% compared to the previous year. Zijin Gold International (02259) issued a profit alert, expecting its 2025 net profit attributable to owners to be approximately $1.5 billion to $1.6 billion, an increase of about 212% to 233% year-on-year.